Aspira Women’s Health (NASDAQ:AWH) Rating Increased to Hold at StockNews.com

Aspira Women’s Health (NASDAQ:AWH) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Wednesday.

Aspira Women’s Health Price Performance

Aspira Women’s Health stock opened at $1.09 on Wednesday. Aspira Women’s Health has a 1-year low of $0.86 and a 1-year high of $6.75. The firm has a market capitalization of $15.57 million, a P/E ratio of -0.75 and a beta of 1.54. The company’s 50-day moving average is $1.45 and its 200 day moving average is $2.81.

Aspira Women’s Health (NASDAQ:AWH) last issued its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million for the quarter, compared to analysts’ expectations of $2.60 million. During the same period last year, the business posted ($0.28) earnings per share. Research analysts anticipate that Aspira Women’s Health will post -1.3 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. Quantum Private Wealth LLC raised its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 76.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 50,156 shares of the company’s stock after acquiring an additional 21,788 shares during the period. Quantum Private Wealth LLC owned approximately 0.49% of Aspira Women’s Health worth $205,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.